EUVIMEDEUVIMED entdecken
Crossref

Use of a Transgenic Human PNPLA3 I148M Knock-in Mouse for Translational Safety Evaluations of siRNA Therapeutics

Ben Brooks, Artem Shkumatov, Jackson Kalanzi, Kim Henderson Park, Julie M Lade, Diana Wong, Hui Dou, Jason Long, Ingrid C Rulifson iD, Justin K Murray, Lauren Mihalcik, Tod A Harper iD

Nucleic Acid Therapeutics · 2025

DOI: 10.1177/21593337251375804 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, 2025. Verfasst von Ben Brooks und 11 weiteren Autor:innen. Beteiligte Einrichtung: Translational Safety & Risk Sciences, Amgen, Inc, Thousand Oaks, California, USA. Hauptthemen laut MEDLINE: RNA, Small Interfering, Lipase, Membrane Proteins, Fatty Liver. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The PNPLA3 single nucleotide polymorphism, rs738409, is the strongest known genetic risk factor for metabolic dysfunction-associated steatotic liver disease; thus, targeting the minor allele with a GalNAc-conjugated siRNA is an attractive strategy to treat patients carrying the genetic variant. To enable translational safety assessment of a GalNAc-conjugated siRNA that specifically targets the rs738409 sequence of PNPLA3, a transgenic human PNPLA3I148M knock-in mouse (huPNPLA3I148M) was utilized. This model showed no significant genotype-related phenotypic differences to wild-type mice in a phenotype characterization study when maintained on standard rodent chow. Additionally, a repeat-dose toxicology study using a GalNAc-conjugated siRNA specific for rs738409 resulted in comparable findings between genotypes (i.e., liver enzyme and histopathology changes), indicating the findings were due to the siRNA therapeutic and not a result of target knockdown in huPNPLA3I148M mice. Overall, these data demonstrate the huPNPLA3I148M mouse is suitable for repeat-dose toxicology studies, suggesting this approach could be applied to other siRNA programs lacking a pharmacologically relevant nonclinical species to support translational safety assessments during drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Small InterferingLipaseMembrane ProteinsFatty LiverAnimalsHumansMiceMice, TransgenicGene Knock-In TechniquesPolymorphism, Single NucleotideLiverAcetylgalactosamineTranslational Research, BiomedicalMaleAcyltransferasesPhospholipases A2, Calcium-Independent

Stichwörter der Autor:innen

nonclinical safetyoligonucleotide-based therapeuticssiRNAtransgenic models

Substanzen

RNA, Small InterferingLipaseMembrane ProteinsPNPLA3 protein, humanAcetylgalactosamineAcyltransferasesPhospholipases A2, Calcium-Independent

Autor:innen und Institutionen

  • Translational Safety & Risk Sciences, Amgen, Inc, Thousand Oaks, California, USA.
  • Translational Safety & Risk Sciences, Amgen, Inc, South San Francisco, California, USA.
  • Pharmacokinetics & Drug Metabolism, Amgen, Inc., South San Francisco, California, USA.
  • Lead Discovery & Characterization, Amgen, Inc., South San Francisco, California, USA.
  • Genetic Medicine, Therapeutic Discovery, Amgen, Inc., Thousand Oaks, California, USA.
  • Cardiometabolic Disorders, Amgen, South San Francisco, California, USA.

ORCID-Profile: Ingrid C Rulifson, Tod A Harper

Zitieren

APA

Brooks, B., Shkumatov, A., Kalanzi, J., Henderson Park, K., Lade, J. M., Wong, D., Dou, H., Long, J., Rulifson, I. C., Murray, J. K., Mihalcik, L., & Harper, T. A. (2025). Use of a Transgenic Human PNPLA3 I148M Knock-in Mouse for Translational Safety Evaluations of siRNA Therapeutics. Nucleic Acid Therapeutics. https://doi.org/10.1177/21593337251375804

Vancouver

Brooks B, Shkumatov A, Kalanzi J, Henderson Park K, Lade JM, Wong D, et al. Use of a Transgenic Human PNPLA3 I148M Knock-in Mouse for Translational Safety Evaluations of siRNA Therapeutics. Nucleic Acid Therapeutics. 2025. doi:10.1177/21593337251375804

BibTeX
@article{Brooks2025,
  author = {Brooks, Ben and Shkumatov, Artem and Kalanzi, Jackson and Henderson Park, Kim and Lade, Julie M and Wong, Diana and Dou, Hui and Long, Jason and Rulifson, Ingrid C and Murray, Justin K and Mihalcik, Lauren and Harper, Tod A},
  title = {Use of a Transgenic Human PNPLA3 I148M Knock-in Mouse for Translational Safety Evaluations of siRNA Therapeutics},
  journal = {Nucleic Acid Therapeutics},
  year = {2025},
  doi = {10.1177/21593337251375804}
}
Kostenlos starten →